Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk
Eric P. Brass(National Jewish Health), William R. Hiatt(University of Colorado Denver), Raymond J. Lipicky, Robert A. Lewis(Middlemore Hospital), James R. Murphy(University of Liverpool)
Cited by 22
Related Papers
Genetic Epidemiology of COPD (COPDGene) Study Design
|COPD Journal of Chronic Obstructive Pulmonary Disease|2010|1.3k
Rivaroxaban in Peripheral Artery Disease after Revascularization
|New England Journal of Medicine|2020|966
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. I. Laboratory and Epidemiologic Observations
|Clinical Infectious Diseases|1983|754
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
|New England Journal of Medicine|2016|628